# Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)

> **NCT03833336** · PHASE3 · COMPLETED · sponsor: **Institut de Recerca Biomèdica de Lleida** · enrollment: 72 (actual)

## Conditions studied

- Heart Failure With Normal Ejection Fraction
- Ferropenic Anemia

## Interventions

- **OTHER:** Placebo
- **DRUG:** Ferric carboxymaltose
- **DRUG:** Ferroglycine Sulfate
- **DRUG:** Sucrosomial Iron

## Key facts

- **NCT ID:** NCT03833336
- **Lead sponsor:** Institut de Recerca Biomèdica de Lleida
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-23
- **Primary completion:** 2024-09-15
- **Final completion:** 2024-12-20
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2025-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833336

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833336, "Effects of Iron Therapy in Heart Failure With Preserved Ejection Fraction and Iron Deficiency (PREFER-HF)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03833336. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*